Clearmind Medicine (NASDAQ:CMND) Major Shareholder Financial Lp Hrt Sells 22,139 Shares of Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 22,139 shares of Clearmind Medicine stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total transaction of $73,280.09. Following the sale, the insider directly owned 81,353 shares in the company, valued at approximately $269,278.43. This trade represents a 21.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, June 15th, Financial Lp Hrt sold 3,183 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.32, for a total transaction of $10,567.56.
• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.36, for a total transaction of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total value of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt acquired 2,159,052 shares of Clearmind Medicine stock. The shares were bought at an average price of $0.15 per share, for a total transaction of $323,857.80.

Clearmind Medicine Stock Down 2.2%

Shares of NASDAQ:CMND opened at $3.07 on Friday. Clearmind Medicine Inc. has a 52-week low of $2.10 and a 52-week high of $524.00. The stock has a market cap of $3.13 million, a P/E ratio of -0.02 and a beta of 0.64. The business has a fifty day moving average of $5.56 and a two-hundred day moving average of $14.82.

Clearmind Medicine (NASDAQ:CMND) last announced its quarterly earnings results on Monday, June 15th. The company reported ($6.78) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a research report on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.